RESUMO
Human papilloma virus was detected by polymerase chain reaction in patients suffering from chronic cystitis with hyperplastic changes in urinary bladder mucosa. In most of the examinees (90%) it was HPV of highly oncogenic type 16. Panavir added to combined treatment of such patients produced a significant positive result in long-term period. Improvement was observed both in subjective assessment and the absence of dysuria episodes.
Assuntos
Antivirais/administração & dosagem , Cistite/tratamento farmacológico , Cistite/patologia , Glicosídeos/administração & dosagem , Papillomavirus Humano 16 , Infecções por Papillomavirus/tratamento farmacológico , Infecções por Papillomavirus/patologia , Cistite/virologia , Feminino , Humanos , Hiperplasia , Mucosa/patologia , Mucosa/virologia , Bexiga Urinária/patologia , Bexiga Urinária/virologiaRESUMO
A total of 55 patients aged 20-59 years with recurrent chronic bacterial prostatitis (RCBP) entered a trial of immunomodulator panavir. The study group consisted of 40 patients. They were given standard treatment and panavir. The control group (n = 15) matched by all the studied characteristics received standard treatment only. Blood count, bacteriological characteristics of prostatic secretion, immunological status, subjective parameters were studied. RCBP patients were diagnosed to have marked disorders of interferon status. The addition of panavir to standard treatment of RCBP patients significantly improved treatment results. Therefore, panavir is recommended as an adjuvant in combined RCBP treatment.
